美電腦防毒軟件商McAfee再被私有化 連債估值逾140億美元
美國電腦防毒軟件商McAfee(MCFE.US)表示,美國私募基金Advent International牽頭財團將以逾140億美元把公司私有化。
財團將以每股26美元現金收購股東手上的股份,單計股份市值約120億美元,收購價較該股上週四(4日)收市價有22.6%溢價。《華爾街日報》翌日報道有關私有化消息。
McAfee於1987年由John McAfee創辦,公司其後上市。英特爾(INTC.US)在2011年收購併將之私有化。McAfee剛於去年重返資本市場。
McAfee昨日(8日)收報25.5美元,略低於私有化作價26美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.